About Dr. Nagendra S Ningaraj
About Dr. Nagendra S Ningaraj

Personal Details

Dr. Nagendra S Ningaraj has succeeded in transforming challenges into great opportunities for the organizations, that he has served. He has thrived on managerial and collaborative role in a multifunctional team environment with passion and innovation. He also had leadership roles in preclinical, immune and clinical oncology R&D projects at University of Kansas-Pharmacy School, Cedars-Sinai, Vanderbilt University, Memorial Health University, Mercer University Medical Centers, Dr. Reddy’s Laboratories, Scintilla Academy and Scintilla Bio-MARC Pvt. Ltd.

  • Pharmacology & Toxicology and Medicine Chemistry postdoctoral fellowships at University of Kansas
  • Directed anti-cancer drug development and medical affairs team for Biologics/biosimilars Division at Dr. Reddy’s lab- directed a team of 20
  • Directed clinical collaborations in academic and CRO settings- used preclinical brain and breast cancer models to evaluate toxicity and mechanism: - MK801 (Merck) -target: Glutamate receptors - Radiolabeled and non-radiolabeled Temozolomide (Schering-Plough Research Institute): target glioma and delivery to brain tumors - Sunitinib malate (SUGEN)-target delivery and effect on PDGFR in brain tumors
  • Performed IVD of infectious (HPV, HCV, HBV, HIV) and non-infectious diseases, validation of molecular and RUO MDx in Oncology at Scintilla Bio-MARC in collaboration with Neuberg Supratech, a CAP-approved lab on PCR-7500 Dx, FACS and ELISA platforms
  • Directed Human Tissue banking/ repository
  • Published more than 75 research articles and presented in many national and international meetings
  • Entrepreneurship- launched Scintilla Academy and Scintilla Bio-MARC Pvt. Ltd.